• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Evolutionary Action Score of < em > TP53 < /em > Analysis in Pathologically High-Risk Human Papillomavirus-Negative Head and Neck Cancer From a Phase 2 Clinical Trial: NRG Oncology Radiation Therapy Oncology Group 0234
CONCLUSIONS: The docetaxel arm was associated with better survival than the cisplatin arm for patients with wild-type or low-risk EAp53. These benefits appear to be largely driven by a reduction in DM.PMID:36420184 | PMC:PMC9677209 | DOI:10.1016/j.adro.2022.100989
Source: Adv Data - November 24, 2022 Category: Epidemiology Authors: Chieko Michikawa Pedro A Torres-Saavedra Natalie L Silver Paul M Harari Merrill S Kies David I Rosenthal Quynh-Thu Le Richard C Jordan Dzifa Y Duose Saradhi Mallampati Sanchit Trivedi Rajyalakshmi Luthra Ignacio I Wistuba Abdullah A Osman Olivier Lichtarg Source Type: research

The Number of Radiographically Positive Lymph Nodes Further Stratifies Patient Survival Among Clinical N1 Patients With Human Papillomavirus-Associated Oropharyngeal Cancer
CONCLUSIONS: The number of radiographically positive lymph nodes is predictive of PFS and overall survival and could be used to meaningfully subcategorize cN1 patients with HPV(+)OPSCC. We recommend further validation of our proposal that cN1 patients with 1 to 2 radiologically positive lymph nodes be categorized as cN1a, patients with 3 to 4 radiologically positive lymph nodes categorized as cN1b, and patients with >4 radiographically positive lymph nodes categorized as cN1c.PMID:35814859 | PMC:PMC9260100 | DOI:10.1016/j.adro.2022.100926
Source: Adv Data - July 11, 2022 Category: Epidemiology Authors: Roman O Kowalchuk Kathryn M Van Abel Adam B Sauer Linda X Yin Joaquin J Garcia William S Harmsen Eric J Moore Daniel L Price Ashish V Chintakuntlawar Katharine R Price Scott C Lester Michelle Neben Wittich Samir H Patel Robert L Foote Daniel M Ma Alex A N Source Type: research

Therapeutic approaches for the treatment of head and neck squamous cell carcinoma-An update on clinical trials
Transl Oncol. 2022 Apr 20;21:101426. doi: 10.1016/j.tranon.2022.101426. Online ahead of print.ABSTRACTHead and neck squamous cell carcinoma (HNSCC) is the sixth most common non-skin cancer with a tobacco consumption and infection with high-risk human papillomavirus (HPV) being major risk factors. Despite advances in numerous therapy modalities, survival rates for HNSCC have not improved considerably; a vast number of clinical outcomes have demonstrated that a combination strategy (the most well-known docetaxel, cisplatin, and 5-fluorouracil) is the most effective treatment choice. Immunotherapy that targets immunological c...
Source: Translational Oncology - April 23, 2022 Category: Cancer & Oncology Authors: Bharat Goel Anoop Kumar Tiwari Rajeev Kumar Pandey Akhand Pratap Singh Sujeet Kumar Abhishek Sinha Shreyans K Jain Arun Khattri Source Type: research

Detectable Post-operative Circulating Tumor Human Papillomavirus (HPV) DNA And Association with Recurrence in Patients with HPV-Associated Oropharyngeal Squamous Cell Carcinoma
CONCLUSION: Amongst patients with detectable pre-op ctHPVDNA, a significant proportion have detectable post-op ctHPVDNA in paired post-op samples, collected prior to the initiation of adjuvant radiation therapy. Future prospective study is warranted to investigate the association of detectable post-op ctHPVDNA with recurrence, including in comparison to established clinical and pathologic risk factors.PMID:35157995 | DOI:10.1016/j.ijrobp.2022.02.012
Source: Health Physics - February 14, 2022 Category: Physics Authors: D M Routman S Kumar B S Chera K R Jethwa K M Van Abel K Frechette T DeWees M Golafshar J J Garcia D L Price J L Kasperbauer S H Patel M A Neben-Wittich N L Laack A V Chintakuntlawar K A Price M C Liu R L Foote E J Moore G P Gupta D J Ma Source Type: research